Parkinson's pipeline
Follow Parkinson's programs spanning alpha-synuclein, GBA biology, gene therapy, and mechanistic repurposing.
Top programs in this hub
Starts with the highest-priority programs in the current dataset, then widens into the full bench below.
A genetically targeted Parkinson's program that fits the monitor's mechanism-first framing well.
- Mechanism
- GCase pathway modulation
- Modality
- small molecule
- Next catalyst
- Further efficacy and pharmacodynamic data in GBA-associated Parkinson's disease.
- Last verified
- 20 Apr 2026
Gene-therapy Parkinson's program that gives the watchlist a cleaner exact-grounded GBA1 entry.
- Mechanism
- GBA1 gene replacement
- Modality
- AAV gene therapy
- Next catalyst
- Further safety and biomarker interpretation in GBA1-associated Parkinson's disease.
- Last verified
- 20 Apr 2026
High-visibility Parkinson's program targeting alpha-synuclein pathology.
- Mechanism
- anti-alpha-synuclein antibody
- Modality
- monoclonal antibody
- Next catalyst
- Further progression and functional readouts.
- Last verified
- 20 Apr 2026
What defines this bench
Quick pattern read on the mechanisms and modalities currently showing up most often.
A disease-specific view of the main programs, the common mechanisms, and the related program pages.
All tracked Parkinson's disease programs
Every program in the current watchlist for this disease, in priority order.
A genetically targeted Parkinson's program that fits the monitor's mechanism-first framing well.
- Mechanism
- GCase pathway modulation
- Modality
- small molecule
- Next catalyst
- Further efficacy and pharmacodynamic data in GBA-associated Parkinson's disease.
- Last verified
- 20 Apr 2026
Gene-therapy Parkinson's program that gives the watchlist a cleaner exact-grounded GBA1 entry.
- Mechanism
- GBA1 gene replacement
- Modality
- AAV gene therapy
- Next catalyst
- Further safety and biomarker interpretation in GBA1-associated Parkinson's disease.
- Last verified
- 20 Apr 2026
High-visibility Parkinson's program targeting alpha-synuclein pathology.
- Mechanism
- anti-alpha-synuclein antibody
- Modality
- monoclonal antibody
- Next catalyst
- Further progression and functional readouts.
- Last verified
- 20 Apr 2026
Mechanism-led repurposing program that keeps the Parkinson's pipeline from being only antibody and device narratives.
- Mechanism
- glucocerebrosidase support / lysosomal modulation
- Modality
- small molecule repurposing
- Next catalyst
- Whether clinical and biomarker read-throughs justify a larger disease-modification push.
- Last verified
- 20 Apr 2026
Parkinson's program with direct mechanistic relevance to alpha-synuclein biology rather than only symptomatic management.
- Mechanism
- alpha-synuclein misfolding inhibition
- Modality
- small molecule
- Next catalyst
- Mostly interpretive now, but still important for understanding how far small-molecule alpha-syn strategies can go.
- Last verified
- 20 Apr 2026
Related pages
Research, key targets, Discover, and ways to contribute.
Other disease hubs
Other disease areas in the pipeline.
Track the mix of amyloid, tau, metabolic, and precision-style Alzheimer's programs worth watching.
Disease hub ALS pipelineTrack ALS programs across genetic targeting, stress-response biology, cell therapy, and platform-trial bets.
Disease hub FTD pipelineTrack FTD programs anchored in progranulin, GRN replacement, C9 biology, and other genetics-led strategies.
Disease hub Huntington's pipelineTrack Huntington's programs across gene therapy, antisense, allele-selective, and small-molecule huntingtin-lowering approaches.